Y-mAbs Therapeutics’ (YMAB) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Y-mAbs Therapeutics (NASDAQ:YMAB) in a research note published on Friday morning,Benzinga reports. The brokerage currently has a $22.00 target price on the stock.

Several other brokerages also recently issued reports on YMAB. Wedbush restated an “outperform” rating and issued a $23.00 price target on shares of Y-mAbs Therapeutics in a report on Tuesday, September 10th. Canaccord Genuity Group restated a “buy” rating and set a $26.00 price objective on shares of Y-mAbs Therapeutics in a research note on Tuesday, August 13th. Morgan Stanley lowered their price target on Y-mAbs Therapeutics from $12.00 to $11.00 and set an “underweight” rating on the stock in a research report on Tuesday, August 13th. Canaccord Genuity Group upgraded shares of Y-mAbs Therapeutics to a “strong-buy” rating in a research note on Tuesday, August 13th. Finally, BMO Capital Markets cut their price target on Y-mAbs Therapeutics from $26.00 to $25.00 and set an “outperform” rating for the company in a report on Tuesday, August 13th. One research analyst has rated the stock with a sell rating, six have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $21.14.

Y-mAbs Therapeutics Stock Down 3.9 %

Shares of NASDAQ YMAB traded down $0.45 during midday trading on Friday, hitting $11.14. The stock had a trading volume of 699,093 shares, compared to its average volume of 242,513. Y-mAbs Therapeutics has a fifty-two week low of $5.04 and a fifty-two week high of $20.90. The company’s 50-day simple moving average is $13.98 and its 200 day simple moving average is $13.09.

Y-mAbs Therapeutics (NASDAQ:YMAB) last released its quarterly earnings data on Friday, November 8th. The company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02). The company had revenue of $18.46 million during the quarter, compared to the consensus estimate of $23.38 million. Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. During the same quarter in the prior year, the company posted ($0.18) EPS. On average, equities research analysts forecast that Y-mAbs Therapeutics will post -0.64 EPS for the current year.

Insider Buying and Selling at Y-mAbs Therapeutics

In other news, insider Thomas Gad sold 65,000 shares of the business’s stock in a transaction that occurred on Friday, September 13th. The shares were sold at an average price of $13.47, for a total value of $875,550.00. Following the completion of the transaction, the insider now directly owns 97,681 shares in the company, valued at approximately $1,315,763.07. The trade was a 39.96 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Joris Wilms sold 5,000 shares of Y-mAbs Therapeutics stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $14.69, for a total transaction of $73,450.00. Following the completion of the transaction, the chief operating officer now directly owns 30,600 shares in the company, valued at $449,514. This trade represents a 14.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 100,000 shares of company stock valued at $1,338,100 in the last quarter. Company insiders own 22.50% of the company’s stock.

Institutional Trading of Y-mAbs Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the stock. State Street Corp increased its holdings in Y-mAbs Therapeutics by 50.4% in the third quarter. State Street Corp now owns 1,209,781 shares of the company’s stock valued at $15,909,000 after purchasing an additional 405,169 shares during the period. Caligan Partners LP raised its holdings in shares of Y-mAbs Therapeutics by 105.3% during the third quarter. Caligan Partners LP now owns 1,195,253 shares of the company’s stock valued at $15,718,000 after purchasing an additional 613,175 shares during the period. Geode Capital Management LLC raised its stake in Y-mAbs Therapeutics by 6.2% during the 3rd quarter. Geode Capital Management LLC now owns 813,489 shares of the company’s stock worth $10,699,000 after buying an additional 47,846 shares during the period. Dimensional Fund Advisors LP raised its position in shares of Y-mAbs Therapeutics by 15.7% during the second quarter. Dimensional Fund Advisors LP now owns 484,431 shares of the company’s stock worth $5,853,000 after purchasing an additional 65,732 shares during the period. Finally, Millennium Management LLC raised its holdings in Y-mAbs Therapeutics by 23.8% during the second quarter. Millennium Management LLC now owns 349,784 shares of the company’s stock worth $4,225,000 after buying an additional 67,233 shares during the last quarter. Institutional investors and hedge funds own 70.85% of the company’s stock.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.